UFP Technologies, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual report, with unaudited quarterly results including the fourth quarter. Amounts below are in U.S. dollars; financial statement figures are in millions unless noted.
Business context
UFP Technologies designs and custom-manufactures components, devices, subassemblies, and packaging from specialized foams, films, and plastics. Medical products are its primary business; it also serves consumer, automotive, aerospace and defense, industrial, and electronics markets. The company reports one operating and reportable segment.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Net sales | $179.4 million | $198.4 million |
| Gross profit / margin | $44.7 million / 24.9% | $54.0 million / 27.2% |
| Operating income / margin | $16.7 million / 9.3% | $24.7 million / 12.5% |
| Net income | $13.4 million | $19.8 million |
| Diluted earnings per share | $1.77 | $2.63 |
| Cash provided by operations | $25.0 million | $31.2 million |
| Capital expenditures | $4.4 million | $5.8 million |
| Cash and cash equivalents at year-end | $24.2 million | $3.7 million |
| Working capital at year-end | $56.7 million | $36.5 million |
| Total liabilities / stockholders’ equity at year-end | $26.3 million / $176.9 million | $26.8 million / $162.0 million |
At December 31, 2020, no amounts were drawn under the credit facilities; $0.7 million of standby letters of credit was outstanding. The company had an unsecured $50 million revolving facility and had repaid its $20 million term loan. The facility’s maturity was extended to December 31, 2025. The company reported compliance with its financial covenants.
Fourth quarter: 2020 net sales were $45.2 million versus $50.3 million in Q4 2019; net income was $4.2 million versus $5.8 million. Diluted EPS was $0.55 versus $0.77.
Material changes versus the prior comparable period
- Full-year sales declined 9.6%, which management primarily attributed to pandemic-related demand impacts, including delayed or canceled elective medical procedures and customer disruptions in automotive markets.
- Gross margin fell to 24.9% from 27.2%. Management cited higher overhead as a percentage of lower sales, partly offset by improved material and labor costs from manufacturing efficiencies and a better business mix.
- SG&A decreased to $27.5 million from $29.3 million, but rose as a share of sales to 15.3% from 14.7%, reflecting lower sales against relatively fixed expenses.
- Cash from operations decreased to $25.0 million from $31.2 million. Cash increased by $20.5 million during 2020, while investing activities used $4.3 million and financing activities used $0.3 million.
- Medical represented 67.0% of 2020 sales. Medical sales were $120.2 million, down from $128.9 million; automotive sales fell to $14.6 million from $20.0 million. Consumer sales increased modestly to $18.3 million from $17.7 million.
Outlook, risks, contingencies, and unusual items
- No specific numerical 2021 revenue or earnings guidance is provided. Management expected the pandemic to continue to affect operating results, while emphasizing that the scale and duration were uncertain.
- For 2021, the company planned to continue adding manufacturing capacity and pursuing operating efficiencies, and retained the option to pursue complementary acquisitions. Management said cash, expected operating cash flow, and the revolver should fund requirements through the next 12 months, while noting this depends on future performance.
- COVID-19 increased labor, maintenance, cleaning, and sterilization costs and contributed to absenteeism and manufacturing inefficiencies. The company implemented cost reductions, including labor measures, and safety protocols; it reported maintaining operations for its customers.
- The CARES Act allowed deferred employer Social Security taxes; approximately $1.6 million was deferred as of year-end. The filing did not expect a material impact on results or liquidity.
- The interest-rate swap had a reported fair-value liability of approximately $0.5 million and generated $0.4 million of 2020 expense. Since the term loan was repaid, the swap no longer hedged underlying debt; it remains outstanding until canceled or matured.
- Principal risks include pandemic-driven demand and supply disruptions, customer concentration (top ten customers were 38.3% of sales), reliance on a limited number of suppliers for certain foams, raw-material and energy cost volatility, competition, product defects or liability claims, and credit-facility covenant and interest-rate exposure.
- Management said ordinary-course legal matters were not expected to have a material adverse effect. The independent auditor issued unqualified opinions on the financial statements and internal control; it reported no critical audit matters.
Important facts for investors to verify
- Reconcile management’s statement that operating and net income each declined 31.7% with the reported annual figures, which imply declines of approximately 32.3% for both.
- Review full quarterly results and EPS from the filed financial statements: the provided quarterly data text contains unclear or apparently malformed EPS entries for some quarters.
- Track recovery in elective medical procedures and demand across automotive, consumer, and other markets, along with whether gross margins improve as sales recover.
- Confirm cash generation, planned capacity spending, and continued availability of the $50 million revolver; assess covenant headroom and the company’s ability to fund potential acquisitions.
- Monitor the remaining interest-rate swap, supplier availability for specialized foams, and customer concentration and receivable exposure.